Genentech, Baxter Healthcare Corp. deal

The companies will combine GNE's technology and intellectual property relating to Factor VIII

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE